Advances in Medicinal Chemistry. Volume 5 Edited by Allen B. Reitz and Scott L. Dax (The R.W. Johnson Pharmaceutical Research Institute). JAI Press:  Stamford, CT. 2000. x + 201 pp. $115.00. ISBN 0-7623-0593-2.

2000 ◽  
Vol 122 (39) ◽  
pp. 9568-9568 ◽  
Author(s):  
Christian P. Whitman
Keyword(s):  
Medicinal Chemistry ◽  
Pharmaceutical Research ◽  
Pharmaceutical Research Institute ◽  
Johnson Pharmaceutical Research ◽  
Research Institute

From estrogens via alkaloids to enzymes

Biologia ◽  
2006 ◽  
Vol 61 (3) ◽  
Author(s):  
Oskar Markovič
Keyword(s):  
Organic Chemistry ◽  
Pharmaceutical Research ◽  
Slovak Academy ◽  
Chemical Technology ◽  
Pectin Methyl Esterase ◽  
Natural Substances ◽  
Pharmaceutical Research Institute ◽  
Technical University ◽  
Academy Of Sciences ◽  
Research Institute

AbstractThis personal and professional autobiography covers the 57-year period from 1948 to 2005 and includes the studies at the Faculty of Chemical Technology of the Slovak Technical University and the Faculty of Pharmacy of Comenius University, both in Bratislava, as well as the activities at the Regional Pharmaceutical Research Institute and the Institute of Chemistry of the Slovak Academy of Sciences in Bratislava, the Institute of Organic Chemistry and Biochemistry in Prague, Karolinska Institutet in Stockholm and at other research and scientific working places in Slovakia and abroad. It highlights the research on natural substances and enzymes, especially the pectin methyl esterase.

Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer

2000 ◽  
Vol 18 (2) ◽  
pp. 275-275 ◽  
Author(s):  
Barbara Conley ◽  
Joyce O’Shaughnessy ◽  
Sheila Prindiville ◽  
Julia Lawrence ◽  
Catherine Chow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Pilot Trial ◽  
Plasma Concentrations ◽  
Hot Flashes ◽  
Pharmaceutical Research ◽  
Density Lipoprotein ◽  
Relative Decrease ◽  
Pharmaceutical Research Institute ◽  
Johnson Pharmaceutical Research

PURPOSE: N-(4-hydroxyphenyl) retinamide ([4-HPR], Fenretinide; R.W. Johnson Pharmaceutical Research Institute, Springhouse, PA) and tamoxifen (TAM) have synergistic antitumor and chemopreventive activity against mammary cancer in preclinical studies. We performed a pilot study of this combination in women at high risk for developing breast cancer. PATIENTS AND METHODS: Thirty-two women were treated with four cycles of 4-HPR, 200 mg orally (PO) for 25 days of each 28-day cycle, and TAM, 20 mg PO once daily for 23 months beginning after 1 month of 4-HPR alone. Tolerability, dark adaptometry, tissue biopsies, and retinoid plasma concentrations (Cp) were evaluated. RESULTS: Symptomatic reversible nyctalopia developed in two patients (6%) on 4-HPR, but 16 (73%) of 22 patients had reversible changes in dark adaptation, which correlated with relative decrease in Cp retinol (P ≤ .01). Four patients stopped treatment for side effects, and 84% of patients had hot flashes. Other commonly reported (grade ≤ 2) reversible toxicities included skin and ocular dryness, fatigue, and mood changes. Serum high-density lipoprotein increased and cholesterol decreased from baseline to month 4. Baseline mean ± SD Cp retinol was 708 ± 280 ng/mL. Mean ± SD Cp of 4-HPR, N-(4-methoxyphenyl) retinamide (4-MPR), and retinol after 1 month of 4-HPR were 0.34 ± 0.21 μmol/L, 0.28 ± 0.21 μmol/L, and 282 ± 127 ng/mL, respectively. Mean retinoid Cps did not change after 3 months of 4-HPR + TAM. CONCLUSIONS: TAM administration did not affect Cp 4-HPR or 4-MPR. Reversible nyctalopia correlated with relative decrease in Cp retinol but was not symptomatic for most patients. TAM + 4-HPR has acceptable tolerability for this high-risk cohort.

Sign in / Sign up

Export Citation Format

Share Document